6996 — Antengene Share News
0.000.00%
Last trade - 00:00- HK$1.93bn
- HK$1.39bn
- CNY105.34m
Brief: Antengene Gets Ind Approval For Phase I Stamina-001 Study To Evaluate Atg-037 In China
Brief: Antengene Says U.S. FDA Ind Clearance For Phase I Trial Of Atg-017
Brief: Antengene Receives U.S. FDA Clearance Of IND Application For Phase I Trial Of ATG-017 In Patients With Advanced Solid Tumors
Brief: Antengene Corp Says Taiwan Food And Drug Administration Approved New Drug Application
Brief: Antengene Corp Confirms That Is Not Aware Of Any Reasons For Price And Volume Movements
Brief: Antengene Corp Posts HY Adjusted Loss RMB126.3 Million
Brief: Antengene Corp Says Unit Entered Into Agreement With Zhejiang Zhongnan Construction Group Co
Brief: Antengene Corp Says Revenue For Six Months Expected To Be Within RMB53.0 Mln To RMB55.0 Mln
Brief: Antengene Announces Research Collaboration With Celularity To Evaluate Potential Therapeutic Synergy Of Combining Antengene's Best-In-Class Bispecific Antibody With Celularity's Natural Killer Cell Platform
Brief: Antengene Announces Clinical Trial Collaboration With Beigene To Evaluate Selinexor In Combination With Tislelizumab In T And Nk-Cell Lymphoma
Brief: Antengene Says China Nmpa Approved A Phase Ii Open-Label Study Of Compound Atg-016 In Patients
Brief: Antengene Posts Loss For Year Of RMB 655.5 Million
Brief: Antengene Corp Says China NMPA Has Approved Phase I Study Of ATG-101 For Treatment Of Advanced Solid Tumors
Brief: Antengene Announces Xpovio® Approved By The TGA In Australia For The Treatment Of Relapsed And/Or Refractory Multiple Myeloma And Triple Class-Refractory Multiple Myeloma
Brief: Antengene Corp Says Australia's TGA Has Registered XPOVIO (Selinexor) For Two Indications
Brief: Antengene Corp Says Singapore Health Sciences Authority Approved Co's New Drug Application
Brief: Antengene Says NMPA Granted Marketing Approval For Selinexor (Atg-010) In China
Brief: Antengene Corp Announces Approval Of Phase I/II Study Of Selinexor (ATG-010) In China
Brief: Antengene Gets NMPA's Approval For Open-Label Phase Ib Dose-Escalation Study Of ATG-008 (Onatasertib) In Combination With ATG-010 (Selinexor)